
Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Ocular Therapeutix | OTX-TIC (travoprost intracameral implant) | glaucoma and ocular hypertension | Phase I trial initiated |
Galapagos NV and MorphoSys AG | MOR106 | moderate-to-severe atopic dermatitis (AD) | Phase II trial initiated evaluating 180 subjects |
ThromboGenics NV | THR-317 administered in combination with ranibizumab (Lucentis, Novartis) | Diabetic Macular Edema (DME) | Phase II trial initiated enrolling 70 subjects |
Wize Pharma, Inc. | LO2A | Symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome | Phase IV trial initiated enrolling 60 subjects in the Israel |
Immusoft Corporation | Immune System Programming | MPS I (Mucopolysaccharidosis type I) | Orphan Drug Designation granted by the FDA |
Stealth Biotherapeutics | elamipretide | Leber’s hereditary optic neuropathy (LHON) | Orphan Drug Designation granted by the FDA |
Conavi TM Medical Inc. | Novasight Hybrid System | simultaneous imaging of coronary arteries with both intravascular ultrasound (VUS) and Optical Coherence Tomography (OCT) | 510(k) clearance granted by the FDA |
Jazz Pharmaceuticals | Xyrem (sodium oxybate) oral solution | cataplexy and Excessive Daytime Sleepiness (EDS) in pediatric narcolepsy patients | sNDA filed with the FDA |
Acceleron Pharma Inc. | ACE-083 | Facioscapulohumeral muscular dystrophy (FSHD) treatment | Fast Track Designation granted by the FDA |
SCYNEXIS, Inc. | Oral SCY-078 | vulvovaginal candidiasis (VVC) and for the prevention of recurrent VVC | Fast Track Designation and Qualified Infectious Disease Product (QIDP) granted by the FDA |
Upcoming Events
-
05Dec
-
14Apr